Mission Bio's Tapestri Platform Used to Distinguish Acute Myeloid Leukemia Clones from CHIP Clones

New findings pave way to potentially improved assessment of measurable residual disease in AML patients

SOUTH SAN FRANCISCO, Calif., May 25, 2021 /PRNewswire/ -- Mission Bio, the life sciences company delivering single-cell resolution multi-omics tools to accelerate discoveries and improve time-to-market for new therapeutics, announced today a new peer-reviewed study published using the Tapestri Platform's single-cell multi-omics solution to accurately distinguish leukemic cells from clonal hematopoiesis of indeterminate potential (CHIP) in relapsed AML patients. These findings highlight the potential of single-cell proteogenomics to vastly improve disease monitoring post-treatment, specifically for measurable residual disease (MRD) in hematological malignancies. The study was led by Christopher S. Hourigan, MD, DPhil, Chief of Myeloid Malignancies at the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, and published in Blood Cancer Discovery, a journal of the American Association for Cancer Research.

Because the same mutations can occur in both CHIP and AML clones in the same patient, it can be difficult to distinguish between the two, which is critical for monitoring disease persistence after a patient has undergone treatment. Current single-analyte methods of MRD detection, such as bulk DNA sequencing and flow cytometry, don't always provide a clear diagnosis. A recent study highlighted the synergistic use of both flow cytometry and NGS-based methods for detection of residual disease.1 In this NHLBI-led study, lead author Laura Dillon, PhD and team showed that integrating both the DNA variants and the immunophenotypic profile from the same cell enables more comprehensive detection of phenotypically heterogeneous disease, while resolving confounding CHIP clones in the same sample.

By conducting simultaneous single-cell DNA and protein analysis on three relapsed AML patients, researchers were able to determine whether epigenetic mutations co-occurred with other leukemia-defining features like structural variations (translocations, inversions, fusions and copy number) and immunophenotypes at the single-cell level. Where AML is often believed to arise from antecedent CHIP populations, one of these samples highlighted a particular case of parallel and mutually exclusive clonal architecture. With these complex genotype-phenotype relationships revealed, they were able to distinguish malignancy from benign somatic mosaicism that can often confound accurate disease profiling. This integrated multi-modal approach provided more comprehensive insight into the clonal relationship between concurrent CHIP and AML clones. Making this distinction can mean the difference in a clinical setting for MRD monitoring of relapsed AML patients, and those living with other heme malignancies that have undergone treatment.

"We are excited that these novel multi-omics methods enabled by Tapestri can provide critical insights to unravel complex disease biology and are showing the potential impact on patient outcomes," said Yan Zhang, CEO of Mission Bio. "They may even open the door to personalized medicines by defining the unique features of MRD in individual patients more accurately. We applaud Dr. Hourigan and team for their efforts, and congratulate them for findings that have the potential to provide better diagnoses to those living with AML."

To learn more about Mission Bio and how their Tapestri Platform is helping enhance cancer and rare disease research and unlock pathways to new treatments, visit missionbio.com.

About Mission Bio
Mission Bio is a life sciences company that accelerates discoveries and cures in oncology by equipping researchers with the tools they need to improve how we measure and predict our resistance and response to cancer therapies. Mission Bio's multi-omics approach improves time-to-market for new therapeutics, including innovative cell and gene therapies that provide new pathways to health. Founded in 2014, Mission Bio has secured investment from Novo Growth, Cota Capital, Agilent Technologies, Mayfield Fund, and others.

The company's Tapestri Platform gives researchers around the globe the power to interrogate every molecule in a cell together, providing a comprehensive understanding of activity from a single sample. Tapestri is the only commercialized multi-omics platform capable of analyzing DNA and protein simultaneously, from the same sample at single-cell resolution. The Tapestri Platform is being utilized by customers at leading research centers, pharmaceutical, and diagnostics companies around the world to develop treatments and eventually cures for cancer and other rare diseases. To learn more, visit missionbio.com.

  1. Patkar, N. et al. 2021. Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML). Leukemia.

Media Contact
Consort Partners for Mission Bio
missionbio@consortpartners.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/mission-bios-tapestri-platform-used-to-distinguish-acute-myeloid-leukemia-clones-from-chip-clones-301298713.html

SOURCE Mission Bio

Back to news